Chiu Ching-Wen, Tam Ka-Wai, Lin I-Chan
School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Department of Medical Education, Taipei Veterans General Hospital, Taipei, 112201, Taiwan.
BMC Ophthalmol. 2025 May 27;25(1):317. doi: 10.1186/s12886-025-04146-0.
Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive. Accordingly, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the effectiveness of RBM for DED treatment.
We searched the PubMed, Embase, and Cochrane Library databases for eligible RCTs. The primary outcome was posttreatment changes in tear breakup time (TBUT). We also assessed changes in the values of Schirmer's test (Sch), corneal fluorescein staining scores, and DED-related symptom scores.
We retrieved 12 RCTs with 1368 eyes published during 2012-2023. The results demonstrated that compared with artificial tears, 2% RBM significantly increased the TBUT [standard mean difference (SMD) = 1.42, 95% confidence interval (CI) = 0.20 to 2.64]. Moreover, 2% RBM led to more significant improvements in overall DED-related symptom scores than did artificial tears (SMD = - 1.61, 95% CI = - 2.61 to - 0.61). The differences in the adverse events between the 2% RBM and artificial tears groups were nonsignificant (SMD = 1.23, 95% CI = 0.62 to 2.44).
Topical RBM ophthalmic suspension is a safe and effective treatment for DED patients. Compared to artificial tears, 2% RBM improved TBUT and subjective symptoms of DED. It may be considered as the first-line treatment option for short- TBUT dry eye patients.
瑞巴派特（RBM）是一种可增加眼表黏液分泌的新型药物。然而，局部应用RBM治疗干眼症（DED）的疗效仍不明确。因此，我们对研究RBM治疗DED有效性的随机对照试验（RCT）进行了系统评价和荟萃分析。
我们在PubMed、Embase和Cochrane图书馆数据库中检索符合条件的RCT。主要结局是治疗后泪膜破裂时间（TBUT）的变化。我们还评估了泪液分泌试验（Sch）值、角膜荧光素染色评分和DED相关症状评分的变化。
我们检索到2012年至2023年期间发表的12项RCT，共涉及1368只眼。结果表明，与人工泪液相比，2%RBM显著增加了TBUT[标准均数差（SMD）=1.42，95%置信区间（CI）=0.20至2.64]。此外，2%RBM比人工泪液在总体DED相关症状评分方面带来了更显著的改善（SMD=-1.61，95%CI=-2.61至-0.61）。2%RBM组和人工泪液组之间不良事件的差异无统计学意义（SMD=1.23，95%CI=0.62至2.44）。
局部应用RBM眼药水对DED患者是一种安全有效的治疗方法。与人工泪液相比，2%RBM改善了TBUT和DED的主观症状。对于TBUT短的干眼症患者，它可被视为一线治疗选择。
